about
Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline for the calf pathogens Mannheimia haemolytica and Pasteurella multocida.Mathematical modeling and simulation in animal health. Part III: Using nonlinear mixed-effects to characterize and quantify variability in drug pharmacokinetics.Authors' Reply to Nicolas: "Why Were More than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?"Authors' Reply to Krebs-Brown et al. Comment on: "Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?"Authors' Reply to Yu et al.: "Levothyrox® New and Old Formulations: Are They Switchable for Millions of Patients?"Differential susceptibility to tetracycline, oxytetracycline and doxycycline of the calf pathogens Mannheimia haemolytica and Pasteurella multocida in three growth mediaAuthors' Reply to Coste et al.: "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"Authors' Reply to Nicolas: "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"Authors' Reply to Castello-Bridoux et al.: "Comment on Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"Author's Reply to Trechot: "Comment on Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?Authors' Reply to Lechat et al.: "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"
P50
Q38665480-8149BF2A-3CCD-45C4-9E38-6D27C11CEF0CQ46244052-EEBA48BB-825A-468F-B2B1-BCF347790F11Q91701202-D3D066EA-DF5C-4AC2-9173-93C9B8A8A5B0Q91701226-FB946B59-DBD1-4526-8C91-8EF5337711FEQ91701232-DD16AB8C-CF7D-45AF-8C1C-145FF27B46BCQ91864666-D2089CDB-1E8A-4715-82A1-C0F47B628B20Q92506774-75571C46-E2B3-4139-A137-3D26FCE94C29Q92506780-04B4928B-E1A8-473E-A2A4-2D0A6DFB83DEQ92675140-A2EA6F9A-7A48-4765-AB95-D1B797D9A137Q92675152-AA2ABA8C-3266-4D34-92A0-CB1181F08756Q92740204-D09AA6DB-FE5C-41AC-B46F-DE3C8BC67B03Q92866132-FE95BB9B-E15C-4D4A-9979-044E281AE5AEQ92886085-69FC561A-C7BC-4B54-8095-D42F2279CC1A
P50
description
researcher
@en
name
P L Toutain
@en
type
label
P L Toutain
@en
prefLabel
P L Toutain
@en
P31
P496
0000-0002-8846-8892